JAC Advance Access published online on May 5, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh232
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medical
Microbiology, Southmead Hospital, Bristol BS10 5NB;
Objectives: To describe the current
patterns of antimicrobial resistance in the major pathogens of bacteraemia
in the UK and Ireland, to highlight any unexpected resistance patterns
and to act as a reference baseline for future studies. Methods: In 2001 and 2002, 5092 blood culture
isolates were collected by 29 laboratories distributed across the
UK and Ireland. A single central laboratory re-identified the isolates
and measured MICs by the BSAC agar dilution method. Results: Oxacillin resistance was found in 42% of Staphylococcus aureus and 76% of coagulase-negative staphylococci.
Streptococci were generally susceptible to Conclusion: Antimicrobial resistance among major
bloodstream pathogens to those antimicrobials often selected for
empirical therapy was relatively uncommon in 2001-2002,
usually <10%. An important exception was oxacillin
resistance in S. aureus.
Accepted March 9, 2004
Original article
Antimicrobial susceptibility of the pathogens of
bacteraemia in the
UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance
Programme
2 Antibiotic Resistance Monitoring & Reference
Laboratory, Health Protection Agency, 61 Colindale Avenue, London
NW9 5HT, UK
Abstract 
-lactams,
but tetracycline resistance was common (except in Streptococcus
pneumoniae) and particularly common among group B isolates
(82% resistant). Nine percent of S. pneumoniae had
reduced susceptibility to penicillin (MICs 0.12-1 mg/L),
but none required 
2 mg/L for inhibition.
High-level gentamicin resistance was seen in 43% of Enterococcus faecalis,
often in combination with raised ciprofloxacin MICs (32
mg/L), but these isolates remained susceptible to ampicillin and
imipenem. Only linezolid and tigecycline showed in vitro potency
against a large proportion of Enterococcus faecium.
Vancomycin resistance was restricted to enterococci (20% of
E. faecium, 3% of E.
faecalis) and a single isolate of coagulase-negative staphylococci
(0.2%, MIC of 8 mg/L). Escherichia coli isolates
were commonly resistant to amoxicillin (56%) and tetracycline
(88%) but remained susceptible to ceftazidime, piperacillin/tazobactam
and imipenem. Extended-spectrum -lactamases
were detected in 2% of E. coli (none in
2001, 3.2% in 2002), 5% of Klebsiella spp.
and 8% of Enterobacter spp. Resistance
rates of Pseudomonas aeruginosa to ciprofloxacin,
ceftazidime, gentamicin, imipenem and piperacillin/tazobactam were
between 4% and 7%. Among the newly licensed and
developmental agents, there was no resistance to linezolid in Gram-positive
organisms. Ertapenem had a wide spectrum, covering Enterobacteriaceae,
streptococci and oxacillin-susceptible staphylococci. MICs of tigecycline
were low for Gram-positive species and Enterobacteriaceae except
Proteeae and Enterobacter spp.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J. Antimicrob. Chemother., August 1, 2008; (2008) dkn311v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo Global Challenge of Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484. [Full Text] [PDF]
|
|
|
|
|
|
P. Moreillon, W. R. Wilson, R. Leclercq, and J. M. Entenza Single-Dose Oral Amoxicillin or Linezolid for Prophylaxis of Experimental Endocarditis Due to Vancomycin-Susceptible and Vancomycin-Resistant Enterococcus faecalis Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1661 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, M. Warner, S. Mushtaq, S. North, and N. Woodford In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1112 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vouillamoz, P. Moreillon, M. Giddey, and J. M. Entenza Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci J. Antimicrob. Chemother., December 1, 2006; 58(6): 1208 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. C. Potz, R. Hope, M. Warner, A. P. Johnson, D. M. Livermore, and on behalf of the London & South East ESBL Project Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England J. Antimicrob. Chemother., August 1, 2006; 58(2): 320 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, A. N. Nafziger, G. L. Drusano, L. Ma, and J. S. Bertino Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1222 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Alou, L. Aguilar, D. Sevillano, M.-J. Gimenez, F. Cafini, E. Valero, M.-T. Relano, and J. Prieto Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration J. Antimicrob. Chemother., April 1, 2006; 57(4): 714 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Jones, M. Tuckman, A. Y. M. Howe, M. Orlowski, S. Mullen, K. Chan, and P. A. Bradford Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections Antimicrob. Agents Chemother., February 1, 2006; 50(2): 505 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. J. Brown, D. I. Edwards, P. M. Hawkey, D. Morrison, G. L. Ridgway, K. J. Towner, M. W. D. Wren, and on behalf of the Joint Working Party of the Britis Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA) J. Antimicrob. Chemother., December 1, 2005; 56(6): 1000 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother., October 1, 2005; 56(4): 611 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pankey Tigecycline J. Antimicrob. Chemother., September 1, 2005; 56(3): 470 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, A. Pearson, and G. Duckworth Surveillance and epidemiology of MRSA bacteraemia in the UK J. Antimicrob. Chemother., September 1, 2005; 56(3): 455 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Whitehouse, J. A. Cepeda, R. Shulman, L. Aarons, R. Nalda-Molina, C. Tobin, A. MacGowan, S. Shaw, C. Kibbler, M. Singer, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill J. Antimicrob. Chemother., March 1, 2005; 55(3): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Woodford, M. E. Ward, M. E. Kaufmann, J. Turton, E. J. Fagan, D. James, A. P. Johnson, R. Pike, M. Warner, T. Cheasty, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum {beta}-lactamases in the UK J. Antimicrob. Chemother., October 1, 2004; 54(4): 735 - 743. [Abstract] [Full Text] [PDF]
|
|